Delafloxacin is used to treat bacterial infections, particularly acute bacterial skin and skin structure infections (ABSSSI). It is effective against a broad range of bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), which makes it valuable in treating infections that are resistant to other antibiotics. Due to its dual solubility in both acidic and neutral environments, delafloxacin achieves higher concentrations in infected tissues, especially in acidic environments commonly found at infection sites. It is available in both intravenous and oral forms, allowing for flexible treatment options, including transition from IV to oral therapy in hospitalized patients. Its activity against both Gram-positive and Gram-negative pathogens broadens its utility in empiric and targeted antimicrobial therapy.